Enanta Pharmaceuticals, Inc. (ENTA) Stock

Enanta Pharmaceuticals, Inc. (ENTA) is a Healthcare stock trading at $13.40 (as of 2026-08-21), with a market capitalization of $390.28M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Enanta Pharmaceuticals, Inc. is a biotechnology company that discovers and develops small-molecule medicines for viral infections and liver diseases. Its research and development programs include targets such as respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus, and it also has a collaboration and licensing arrangement with Abbott Laboratories for hepatitis C virus protease inhibitor compounds.

Understand Enanta Pharmaceuticals, Inc.: how it makes money

Enanta Pharmaceuticals discovers and develops small-molecule drugs for viral infections and liver diseases, and it earns royalties tied to AbbVie product sales under its hepatitis C collaboration.

The companys near-term profit engine is contract royalties linked to AbbVie net product sales from specific hepatitis C drugs, while ongoing operating losses reflect that most value creation is still driven by clinical development risk in its pipeline.

Revenue by segment (latest quarter)
AbbVie Maverick Royalties	$0.0B
MAVYRET/MAVIRET Royalties	$0.0B

Business quality (Weak): Royalty segment candidates are provided, but the latest-quarter total revenue is shown as 0.0B, which suggests rounding or incomplete aggregation, so treat the small revenue figures as approximate.

Bull case

Royalty revenue lines are tied to AbbVies Maverick net product sales and its MAVYRET and MAVIRET products, creating at least some non-trial revenue linkage to commercial performance: This is reflected in the presence of multiple royalty revenue segment candidates in the latest period.
For its RSV program, Zelicapavir shows trial signals versus placebo across multiple study metrics provided: Examples include a Respiratory Syncytial Virus related hospitalization rate of 0.0% in the Zelicapavir group versus 5.0% in the placebo group, and undetectable viral load at end of treatment of 23.5% in the efficacy population for Zelicapavir.

Bear case

Operating profitability is weak in the latest quarter: Operating margin is -69.1% for the quarter ended 2026-03-31.
Total reported revenue is effectively zero in the latest-quarter financials, which can leave the company more dependent on future commercial milestones and/or trial outcomes: Revenue is shown as 0.0B for the quarter ended 2026-03-31, while royalty amounts appear small and may be sensitive to AbbVie product sales.
Clinical program success is uncertain, even when individual endpoints look favorable: The provided operating metrics include specific RSV clinical endpoints and viral load measures, but investors must still treat them as contingent on the broader clinical development and regulatory pathway.

Valuation — source: SEC EDGAR (first-party)
Price	$13.40
Market Cap	$390.28M
Price / Book	3.86
Price / Sales	5.80
FCF Yield	-20.2%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$65.32M
Net Margin	-125.4%
Revenue Growth (YoY)	-21.6%
EPS Growth (YoY)	-21.2%
FCF Growth (YoY)	19.7%

Financial Health — source: SEC EDGAR
Altman Z-Score	-1.05 (distress)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Jupiter Topco LLC ($53.25M)
Institutional Holders Tracked	10
Congressional Trades (recent)	1

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Jay R. Luly
Employees	131
Country	US
IPO Date	2013-03-21

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.